Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A. Mackintosh; Gregory Keir; Lauren K. Troy; Anne E. Holland; Christopher Grainge; Daniel C. Chambers; Debra Sandford; Helen E. Jo; Ian Glaspole; Margaret Wilsher; Nicole S.L. Goh; Paul N. Reynolds; Sally Chapman; Steven E. Mutsaers; Sally de Boer; Susanne Webster; Yuben Moodley; Tamera J. Corte

doi:10.1111/resp.14656

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

John A. Mackintosh
, Gregory Keir
, Lauren K. Troy
, Anne E. Holland
, Christopher Grainge
, Daniel C. Chambers
, Debra Sandford
, Helen E. Jo
, Ian Glaspole
, Margaret Wilsher
, Nicole S.L. Goh
, Paul N. Reynolds
, Sally Chapman
, Steven E. Mutsaers
, Sally de Boer
, Susanne Webster
, Yuben Moodley
, Tamera J. Corte

Immunology Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

46 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

Original language	English
Pages (from-to)	105-135
Number of pages	31
Journal	Respirology
Volume	29
Issue number	2
DOIs	https://doi.org/10.1111/resp.14656
Publication status	Published - Feb 2024

Keywords

idiopathic pulmonary fibrosis
interstitial lung disease
progressive pulmonary fibrosis
pulmonary fibrosis
treatment

Access to Document

10.1111/resp.14656Licence: CC BY

Cite this

Mackintosh, J. A., Keir, G., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., Wilsher, M., Goh, N. S. L., Reynolds, P. N., Chapman, S., Mutsaers, S. E., de Boer, S., Webster, S., Moodley, Y., & Corte, T. J. (2024). Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision. Respirology, 29(2), 105-135. https://doi.org/10.1111/resp.14656

@article{64460ba3f72c423a8a1ac44f11965d10,

title = "Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision",

abstract = "Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.",

keywords = "idiopathic pulmonary fibrosis, interstitial lung disease, progressive pulmonary fibrosis, pulmonary fibrosis, treatment",

author = "Mackintosh, \{John A.\} and Gregory Keir and Troy, \{Lauren K.\} and Holland, \{Anne E.\} and Christopher Grainge and Chambers, \{Daniel C.\} and Debra Sandford and Jo, \{Helen E.\} and Ian Glaspole and Margaret Wilsher and Goh, \{Nicole S.L.\} and Reynolds, \{Paul N.\} and Sally Chapman and Mutsaers, \{Steven E.\} and \{de Boer\}, Sally and Susanne Webster and Yuben Moodley and Corte, \{Tamera J.\}",

note = "Funding Information: This position statement was supported by the Centre of Research Excellence in Pulmonary Fibrosis (funded by the NHMRC [GNT1116371 and GNT2015613], Lung Foundation Australia, anonymous philanthropy and Foundation partner Boehringer Ingelheim), The Thoracic Society of Australia and New Zealand and Lung Foundation Australia. Open access publishing facilitated by The University of Queensland, as part of the Wiley - The University of Queensland agreement via the Council of Australian University Librarians. Funding Information: This position statement was supported by the Centre of Research Excellence in Pulmonary Fibrosis (funded by the NHMRC [GNT1116371 and GNT2015613], Lung Foundation Australia, anonymous philanthropy and Foundation partner Boehringer Ingelheim), The Thoracic Society of Australia and New Zealand and Lung Foundation Australia. Open access publishing facilitated by The University of Queensland, as part of the Wiley ‐ The University of Queensland agreement via the Council of Australian University Librarians. Publisher Copyright: {\textcopyright} 2024 The Authors. Respirology published by John Wiley \& Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.",

year = "2024",

month = feb,

doi = "10.1111/resp.14656",

language = "English",

volume = "29",

pages = "105--135",

journal = "Respirology",

issn = "1323-7799",

publisher = "Wiley-Blackwell",

number = "2",

}

Mackintosh, JA, Keir, G, Troy, LK, Holland, AE, Grainge, C, Chambers, DC, Sandford, D, Jo, HE, Glaspole, I, Wilsher, M, Goh, NSL, Reynolds, PN, Chapman, S, Mutsaers, SE, de Boer, S, Webster, S, Moodley, Y & Corte, TJ 2024, 'Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision', Respirology, vol. 29, no. 2, pp. 105-135. https://doi.org/10.1111/resp.14656

TY - JOUR

T1 - Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

T2 - A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

AU - Mackintosh, John A.

AU - Keir, Gregory

AU - Troy, Lauren K.

AU - Holland, Anne E.

AU - Grainge, Christopher

AU - Chambers, Daniel C.

AU - Sandford, Debra

AU - Jo, Helen E.

AU - Glaspole, Ian

AU - Wilsher, Margaret

AU - Goh, Nicole S.L.

AU - Reynolds, Paul N.

AU - Chapman, Sally

AU - Mutsaers, Steven E.

AU - de Boer, Sally

AU - Webster, Susanne

AU - Moodley, Yuben

AU - Corte, Tamera J.

N1 - Funding Information: This position statement was supported by the Centre of Research Excellence in Pulmonary Fibrosis (funded by the NHMRC [GNT1116371 and GNT2015613], Lung Foundation Australia, anonymous philanthropy and Foundation partner Boehringer Ingelheim), The Thoracic Society of Australia and New Zealand and Lung Foundation Australia. Open access publishing facilitated by The University of Queensland, as part of the Wiley - The University of Queensland agreement via the Council of Australian University Librarians. Funding Information: This position statement was supported by the Centre of Research Excellence in Pulmonary Fibrosis (funded by the NHMRC [GNT1116371 and GNT2015613], Lung Foundation Australia, anonymous philanthropy and Foundation partner Boehringer Ingelheim), The Thoracic Society of Australia and New Zealand and Lung Foundation Australia. Open access publishing facilitated by The University of Queensland, as part of the Wiley ‐ The University of Queensland agreement via the Council of Australian University Librarians. Publisher Copyright: © 2024 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Respirology.

PY - 2024/2

Y1 - 2024/2

N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

AB - Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti-fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non-IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non-pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi-faceted approach to the management of IPF and progressive pulmonary fibrosis.

KW - idiopathic pulmonary fibrosis

KW - interstitial lung disease

KW - progressive pulmonary fibrosis

KW - pulmonary fibrosis

KW - treatment

UR - https://www.scopus.com/pages/publications/85182248034

U2 - 10.1111/resp.14656

DO - 10.1111/resp.14656

M3 - Article

C2 - 38211978

AN - SCOPUS:85182248034

SN - 1323-7799

VL - 29

SP - 105

EP - 135

JO - Respirology

JF - Respirology

IS - 2

ER -

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Abstract

Keywords

Access to Document

Other files and links

CRE for Interstitial Lung Disease - towards Individualised Care

Understanding human lung fibroblast responses to hypoxia in ILD

Cite this

Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision

Abstract

Keywords

Access to Document

Other files and links

Projects

CRE for Interstitial Lung Disease - towards Individualised Care

Understanding human lung fibroblast responses to hypoxia in ILD

Cite this